An Acorda Therapeutics drug, Ampyra (dalfampridine), which helps people with multiple sclerosis walk, also helps stroke patients who cannot walk, the company announced. In a proof-of- concept Phase II study, Ampyra (dalfampridine extended release 10mg tablets) significantly improved walking in...
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced the National Heart, Lung, and Blood Institute (NHLBI) has awarded a $1 million Cardiac Translational Research Implementation Program (C-TRIP) grant to support research on Glial Growth Factor 2 (GGF2), a novel investigational agent for the...